"Science for Organizations created a validated method of statistical analyses that enabled me to clearly show the statistical superiority of my drug over the competition. These analyses were subsequently published in peer-reviewed journals and enabled our sales representatives to speak to physicians about the superiority of our drug."
Arthur A. Ciociola, Ph. D.
Vice President
Pfizer, Inc.
"A high level of scientific clinical acumen, combined with a novel way to analyze data, makes Science for Organizations different. They helped us extract new meaning—such as the pharmacology and dose for a new chemical entity—from data in earlier studies where dose response was not even an objective."
William Hahne, M.D.
former Vice President
Clinical Research and Development
Eisai, Inc.
"A complex statistical analysis and interpretation of extensive clinical data performed by Science for Organizations proved to be pivotal in obtaining a key health claim approval from the Food and Drug Administration for our client's product."
Robert G. Edwards, Ph.D.
Director of Regulatory Science
Arent Fox PLLC
"Jerry Gardner and his colleagues at Science for Organizations played a critical role in helping us develop key positions during the Rx-to-OTC switch of Prilosec OTC. His in-depth understanding of the medical implications of our product and the FDA process, as well as creative analyses and new ways of putting data together, allowed us to create a simple and thorough story establishing the suitability of Prilosec in the OTC setting. Jerry's guidance and experience proved invaluable, and I turn to him again and again as we move into new areas."
Lisa Allgood
Associate Director Gastrointestinal R&D
Personal Health Care
Procter & Gamble Health Sciences Institute
